# A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Source: https://onco.cc/trials/nct03473743/  
OnCo record `nct03473743` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Erdafitinib, Cetrelimab, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer is a phase 1/2 interventional study registered as NCT03473743 by Janssen Research & Development, LLC, with 125 participants enrolled, started 2018-04-05 and due to reach its primary completion in 2022-09-30. Interventions recorded: Erdafitinib, Cetrelimab, Cisplatin and Carboplatin. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03473743
- Phase: 1/2
- Setting: A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 125
- Outcomes: Phase 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator Assessment: Arm A (Phase 2): Erdafitinib 8/9 mg Monotherapy 44.2% vs Arm B (Phase 2): Erdafitinib 8 mg + Cetrelimab 240/480 mg 54.5%

## Sources

- ClinicalTrials.gov NCT03473743: https://clinicaltrials.gov/study/NCT03473743

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Muscle-invasive and advanced bladder cancer](https://onco.cc/cancers/muscle-invasive-bladder-cancer/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cetrelimab](https://onco.cc/drugs/cetrelimab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Erdafitinib](https://onco.cc/drugs/erdafitinib/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct03473743.json